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Abstract
Introduction: There is no data on the relationship between hepatitis B surface antigen (HBsAg) levels and liver fibrosis in
hepatitis B e antigen (HBeAg)-positive patients with chronic hepatitis B (CHB).
Methods: Serum HBsAg and HBV DNA levels in HBeAg-positive CHB patients with liver biopsies were analyzed. The upper
limit of normal (ULN) of alanine aminotransferase (ALT) was 30 and 19 U/L for men and women respectively. Histologic
assessment was based on Ishak fibrosis staging for fibrosis and Knodell histologic activity index (HAI) for necroinflammation.
Results: 140 patients (65% male, median age 32.7 years) were recruited. 56 (40%) had ALT #26ULN. 72 (51.4%) and 42
(30%) had fibrosis score #1 and necroinflammation grading #4 respectively. Patients with fibrosis score #1, when
compared to patients with fibrosis score .1, had significantly higher median HBsAg levels (50,320 and 7,820 IU/mL
respectively, p,0.001). Among patients with ALT #26ULN, serum HBsAg levels achieved an area under receiver operating
characteristic curve of 0.869 in predicting fibrosis score #1. HBsAg levels did not accurately predict necroinflammation
score. HBsAg $25,000 IU/mL was independently associated with fibrosis score #1 (p = 0.025, odds ratio 9.042).Using this
cut-off HBsAg level in patients with ALT #26ULN, positive and negative predictive values for predicting fibrosis score #1
were 92.7% and 60.0% respectively. HBV DNA levels had no association with liver histology.
Conclusion: Among HBeAg-positive patients with ALT #26ULN, high serum HBsAg levels can accurately predict fibrosis
score #1, and could potentially influence decisions concerning treatment commencement and reduce the need for liver
biopsy.
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Introduction
Chronic hepatitis B (CHB) is known for its highly variable
disease course, ranging from an inactive carrier state to the
development of clinical complications, including cirrhosis and
hepatocellular carcinoma (HCC) [1]. CHB patients with repeated
hepatitis flares were noted to have increased necroinflammation in
liver histology, leading to increased fibrogenesis and subsequent
disease progression [2].
Treatment guidelines by two international liver associations
[3,4] recommend treatment commencement when serum alanine
aminotransferase (ALT) is persistently .26upper limit of normal
(ULN) in hepatitis B e antigen (HBeAg)-positive patients.
Guidelines from another international liver association recom-
mend treatment when there is clinical evidence of significant liver
fibrosis e.g. by using liver biopsy in patients with elevated ALT [5].
There is increasing evidence that patients with ALT #26ULN
could still eventually develop clinical complications [6]. HBeAg-
positive patients with normal ALT are traditionally classified as in
the immune tolerant phase of disease, with minimal histologic
changes on liver biopsy [7]. However histologic studies of HBeAg-
positive patients with ‘‘high normal’’ ALT have been shown to
have significant fibrosis and necroinflammation [8,9]. In addition,
the definition of ‘‘normal ALT’’ has also been re-evaluated. One
study of 6835 healthy blood donors has suggested lowering the
ULN of ALT to 30 U/L for men and 19 U/L for women [10]. A
study from Asia involving 1105 potential liver donors also has
similar recommendations [11]. Because of all these controversial
issues, using ALT levels to classify patients for treatment initiation
is suboptimal. Assessment of fibrosis is thus an important
parameter in deciding treatment.
Given the invasive nature of liver biopsy, several non-invasive
indices have been developed for the prediction of significant
fibrosis in CHB [12,13,14]. These studies however are limited by
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their small sample sizes, the lack of large-scale external validation,
and the use of serum markers not routinely available from
standard laboratories. The use of predictive models established in
chronic hepatitis C has also produced conflicting results [15,16].
Transient elastography is another method for assessing liver
fibrosis [17]. However, it is often difficult to determine in obese
patients, has reduced diagnostic accuracy with lower fibrosis
scores, and is affected by even small degrees of ALT elevation,
with 40–50% of patients still requiring other means of fibrosis
assessment [17].
The quantification of hepatitis B surface antigen (HBsAg) levels
has been recently advocated as a surrogate marker for intrahepatic
closed covalently circular DNA (cccDNA) [18]. Recent evidence
have shown serum HBsAg levels to be useful in identifying inactive
CHB carriers [19], predicting subsequent HBsAg seroclearance
[20,21,22], and predicting favorable outcomes with pegylated
interferon therapy [23]. Serum HBsAg levels have been shown to
be extremely high among HBeAg-positive patients with normal
ALT [24,25], and it has been suggested high HBsAg levels could
be supportive evidence of immune tolerance [26]. The aim of our
study was to evaluate the use of serum HBsAg levels in assessing
liver histology in HBeAg-positive CHB patients.
Methods
Ethics Statement
The present study was approved by the Institutional Review
Board, the University of Hong Kong and West Cluster of Hospital
Authority, Hong Kong. All patients had written consent prior to
liver biopsy and study entry with all clinical investigation
conducted according to the principles expressed by the Declara-
tion of Helsinki.
Patients
The present study included treatment-naive HBeAg-positive
CHB patients who were recruited for therapeutic drug trials
between 1994 to 2008 in the Department of Medicine, the
University of Hong Kong, Queen Mary Hospital. All patients
were HBsAg-positive for at least 6 months before study entry.
Other inclusion criteria included ALT ,106ULN and HBV
DNA $20,000 IU/mL. Patients with concomitant liver diseases,
including chronic hepatitis C or D infection, Wilson’s disease,
autoimmune hepatitis, primary biliary cirrhosis, significant intake
of alcohol (30 grams per day for male, 20 grams per day for
female) and decompensated liver disease were excluded.
Liver Biopsy
Two different biopsy needles were used. An 18G sheathed
cutting needle (Temno Evolution, Cardinal Health, McGaw Park,
IL) was used in 58 patients, while a 17G core aspiration needle
(Hepafix, B. Braun Melsungen AG, Germany) was used for the
remaining 82 patients. The biopsy lengths were 1.5 to 1.8 cm and
2 to 5 cm respectively. A single pathologist (initials PPCI), blinded
to all biochemical, serologic and virologic parameters, was
assigned to review all biopsy specimens. Biopsies were fixed,
paraffin-embedded, and stained with hematoxylin and eosin for
morphological evaluation and Masson’s trichrome stain for
assessment of fibrosis. Histologic staging of fibrosis and grading
of necroinflammation was performed using the Ishak fibrosis score
(range 0 to 6) [27] and Knodell histologic activity index (HAI)
(range 0 to 18) [28] respectively. ‘‘Insignificant fibrosis’’ was
defined as an Ishak fibrosis score of equal or less than 1.
‘‘Insignificant necroinflammation’’ was defined as a Knodell HAI
score of equal or less than 4.
Laboratory Assays
Serum samples used for measurements were taken at the day of
biopsy and stored at 220uC. Following recommendations of
current treatment guidelines [3], the ULN of serum ALT was
defined as 30 U/L for men and 19 U/L for women [10]. Serum
HBsAg, HBeAg and antibody to the hepatitis B e antigen (anti-
HBe) were measured using commercially available immunoassays
(Abbott Laboratories, Chicago, IL). Serum HBV DNA levels were
measured using Cobas Taqman assay (Roche Diagnostics,
Branchburg, NJ), with a linear range of 20 to 1.986108 IU/mL.
Samples with HBV DNA levels higher than 1.986108 IU/mL
were diluted at 1:100 for retesting. Serum HBsAg titer was
measured using the Elecsys HBsAg II assay (Roche Diagnostics,
Gmbh, Mannheim), with a linear range of 0.05 to 52,000 IU/mL.
Samples with HBsAg levels higher than 52,000 IU/mL were
retested at a dilution of 1:100.
Statistical Analysis
All continuous variables are expressed in median (range).
Statistical analyses were performed using SPSS version 18.0 (SPSS
Inc, Chicago, Illinois). The Mann-Whitney U test was used for
comparing continuous variables with a skewed distribution; Chi
squared test was used for categorical variables. Correlation was
performed using Spearman’s bivariate correlation. The predictions
of minimal histologic changes were first examined by the
construction of corresponding receiver operating characteristic
(ROC) curves, followed by the assessment of overall accuracy by
areas under the curves (AUCs). The Youden Index, defined as the
sensitivity plus the specificity minus one, was used to identify the
optimal level of prediction. Multivariate logistic regression was
used to identify factors independently associated with insignificant
fibrosis. A two-sided p value of ,0.05 was considered statistically
significant.
Results
One hundred and forty HBeAg-positive patients were included
in the present study. The baseline demographics are shown in
Table 1. Three patients (2.1%) had histologic evidence of cirrhosis.
Based on liver biochemistry, 17 (12.1%) were classified as immune
tolerant with normal ALT; the remaining 123 (87.9%) were
classified to be in immune clearance. There were no significant
differences in age, gender, liver biochemistry and serum HBV
DNA between the two groups of patients (Table 1, all p.0.05).
Median HBsAg levels for patients with normal ALT, ALT 1–
26ULN and ALT .26ULN were 105,020 IU/mL (range:
13,490–319,800 IU/mL), 40,490 IU/mL (range: 257–
286,300 IU/mL) and 9,362 IU/mL (range: 62–217,200 IU/mL)
respectively (p,0.001). The distribution of HBsAg levels among
patients stratified by ALT #26ULN versus ALT .26ULN is
shown in Figure 1a. A significantly larger proportion of patients
with ALT #26ULN had serum HBsAg .25,000 IU/mL when
compared to patients with ALT .26ULN (73.2% versus 26.2%,
p,0.001).
Serum HBsAg showed moderate correlation with serum HBV
DNA levels (r = 0.403, p,0.001), and moderate inverse correla-
tion with ALT levels (r =20.450, p,0.001).
Liver Histology
The distribution of fibrosis scores and necroinflammation
gradings of all 140 patients stratified by ALT levels is shown in
Figures 1b and 1c. Seventy-two (51.4%) and 42 (30%) patients had
insignificant fibrosis and necroinflammation respectively. All
immune tolerant patients with normal ALT (n= 17) had
HBsAg Levels and Fibrosis in Chronic Hepatitis B
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insignificant fibrosis. Among patients with ALT #26ULN
(n=56), 44 (78.6%) had insignificant fibrosis, significantly more
than among patients with ALT .26ULN (33.3%, p,0.001). The
proportion of patients with insignificant necroinflammation
among the two patients groups was similar (33.9% and 27.4%
respectively, p= 0.408). The type of biopsy needle used (i.e. the
sheathed cutting needle versus the core aspiration needle) did not
influence the degree of fibrosis and necroinflammation (p= 0.735
and 0.970 respectively). Serum HBsAg levels among all patients
divided by their histologic scores and gradings are shown in
Figures 2a and 2b. Patients with insignificant fibrosis had
significantly higher median HBsAg levels (p,0.001). In the
subgroup of 39 patients with ALT 1–26ULN, median HBsAg
levels were also significantly higher in those with insignificant
fibrosis (51,400 IU/mL, range: 2,598 to 286,300 IU/mL) when
compared to those with significant fibrosis (7,703 IU/mL, range
257 to 78,810 IU/mL) (p = 0.002). Comparing patients with
insignificant necroinflammation and those with significant ne-
croinflammation, median HBsAg levels showed no significant
difference (p = 0.393).
Median serum HBV DNA levels showed no significant
difference in patients with insignificant fibrosis compared to
patients with significant fibrosis for the whole group (8.01 and 7.85
log IU/mL respectively, p= 0.794) and for the subgroup of
patients with ALT #26ULN (8.23 and 7.65 log IU/mL
respectively, p = 0.318). There was also no significant difference
in median HBV DNA levels among patients with insignificant
necroinflammation versus significant necroinflammation for the
whole group of patients (7.91 and 7.99 log IU/mL respectively,
p = 0.897) and for the subgroup of patients with ALT #26ULN
(8.40 and 8.02 log IU/mL respectively, p= 0.095).
Serum HBsAg showed a moderate inverse correlation with
fibrosis scores (r =20.449, p,0.001). Serum HBsAg also had an
inverse correlation with necroinflammation gradings, but with a
lower correlation coefficient (r =20.269, p = 0.001). Serum HBV
DNA had no correlation with both fibrosis scores (r =20.076,
p = 0.373) and necroinflammation gradings (r =20.042,
p = 0.624).
Table 1. Baseline characteristics of all 140 patients.
All patients (n =140) ALT #26ULN (n=56) ALT .26ULN (n=84) p value*
Age 32.7 (16.6–60.1) 32.6 (16.6–55.0) 32.5 (18.0–60.1) 0.309
Number of male patients 91 (65.0%) 40 (71.4%) 51 (60.7%) 0.193
Albumin (U/L) 46 (37–54) 47 (39–52) 45 (37–54) 0.152
Bilirubin (umol/L) 10 (3–31) 9.5 (4–31) 10.5 (3–30) 0.088
ALT (U/L) 67.5 (14–175) 38 (14–60) 89 (46–175) ,0.001
HBV DNA (log IU/mL) 7.96 (4.41–12.4) 8.14 (4.83–11.9) 7.72 (4.41–12.4) 0.113
HBsAg (IU/mL) 17,680 (62–319,800) 52,535 (257–319,800) 9,362 (62–217,200) ,0.001
All continuous values expressed in median (range).
ALT, alanine aminotransferase; ULN, upper limit of normal; HBsAg, hepatitis B surface antigen.
ALT upper limit of normal: 30 U/L for men, 19 U/L for women.
*Comparison was between patients with ALT #26ULN and ALT .26ULN.
doi:10.1371/journal.pone.0043087.t001
Figure 1. Distribution of all patients stratified by ALT levels. HBsAg levels (Figure 1a), fibrosis scores (Figure 1b) and necroinflammation
gradings (Figure 1c) of all patients are shown.
doi:10.1371/journal.pone.0043087.g001
HBsAg Levels and Fibrosis in Chronic Hepatitis B
PLOS ONE | www.plosone.org 3 August 2012 | Volume 7 | Issue 8 | e43087
HBsAg Levels and Fibrosis in Chronic Hepatitis B
PLOS ONE | www.plosone.org 4 August 2012 | Volume 7 | Issue 8 | e43087
Predictive Value of HBsAg for Minimal Histologic
Changes
The ROC curves and the AUC values of serum HBsAg levels in
predicting insignificant fibrosis and necroinflammation are
depicted in Figure 3 and Table 2. Serum HBsAg levels produced
a better AUC for insignificant fibrosis in patients with ALT
#26ULN (AUC 0.869) compared to the overall population (AUC
0.771). Serum HBsAg levels did not have any predictive value for
insignificant necroinflammation (AUC 0.546 and 0.532 for all
patients and patients with ALT #26ULN respectively).
The sensitivity, specificity and predictive values of different
HBsAg levels in predicting insignificant fibrosis among patients
with ALT #26ULN are shown in Table 3. Based on the Youden
Index, the optimal level of serum HBsAg to predict insignificant
fibrosis was $27,490 IU/mL (Youden index 0.697, sensitivity
86.4%, specificity 83.3%). Rounding off to the nearest five-
thousandth level, serum HBsAg $25,000 IU/mL was able to
predict insignificant fibrosis with a sensitivity of 86.4%, specificity
of 75.0%, positive predictive value of 92.7% and negative
predictive value of 60.0%. The 7.3% (3 out of 41) of patients
with HBsAg$25,000 IU/mL but fibrosis score .1 had only stage
2 fibrosis. Serum HBsAg $100,000 IU/mL was 100% predictive
of insignificant fibrosis.
Multivariate Analysis for Predicting Insignificant Fibrosis
Among patients with ALT #26ULN, younger age (p,0.001),
serum HBsAg $25,000 IU/mL (p,0.001) and lower serum ALT
(p= 0.001) were associated with insignificant fibrosis by univariate
analysis. The multivariate analysis of factors independently
predictive of insignificant fibrosis is shown in Table 4. After
adjusting for different clinical parameters, factors independently
associated with insignificant fibrosis included serum HBsAg
$25,000 IU/mL (p= 0.025, odds ratio 9.042, 95% confidence
interval 1.325–61.716) and younger age (p = 0.030).
Discussion
An elevated ALT level classically differentiates immune
clearance from immune tolerance in HBeAg-positive CHB.
Nevertheless, studies have shown ALT to be an inaccurate marker
of liver injury [7,9]. Although HBsAg staining patterns in liver
histology [29] and antibody to the hepatitis B core antigen IgM
titers [30] could assist in differentiating the two HBeAg-positive
disease phases, the assessment of fibrosis remains an essential step
in deciding treatment commencement [5]. Current non-invasive
methods are unable to accurately identify patients with severe
histologic abnormalities. Our present study showed serum HBsAg
levels can play an important role in identifying HBeAg-positive
patients with insignificant fibrosis and potentially reduce the need
for liver biopsies. Although there had been preliminary analysis
linking HBsAg levels with histologic severity [31], our study to our
knowledge was the first to formally use liver histology as an
outcome measure to assess the role of HBsAg titers in distinguish-
ing insignificant and significant fibrosis.
The present study identified two serum HBsAg cut-off levels
useful for predicting insignificant fibrosis among HBeAg-positive
patients with ALT #26ULN. Serum HBsAg $100,000 IU/mL
was 100% predictive of insignificant fibrosis. Prior studies also
found similarly high serum HBsAg levels in immune tolerant
patients defined by normal ALT levels [24,25,32]. HBeAg-positive
patients with HBsAg $100,000 are likely to have insignificant
fibrosis even if ALT levels are minimally elevated.
Figure 2. Distribution of serum HBsAg levels. Patients are stratified by fibrosis scores (Figure 2a) and necroinflammation gradings (Figure 2b).
doi:10.1371/journal.pone.0043087.g002
Figure 3. Receiver operating characteristic curves of serum HBsAg levels in predicting insignificant fibrosis (Ishak fibrosis score
#1).
doi:10.1371/journal.pone.0043087.g003
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The present study also found the optimal serum HBsAg cut-off
level to predict insignificant fibrosis to be of $25,000 IU/mL.
Among HBeAg-positive patients with ALT #26ULN, serum
HBsAg $25,000 IU/mL had a positive predictive value of 92.7%
of predicting insignificant fibrosis. In addition, serum HBsAg
$25,000 IU/mL was the best factor independently associated
with insignificant fibrosis (p = 0.025, odds ratios 9.042). Our results
suggest that HBeAg-positive patients with ALT #26ULN and
serum HBsAg $25,000 IU/mL can be observed without the need
of liver biopsies. If serum HBsAg levels are below 25,000 IU/mL,
other forms of assessment of fibrosis are necessary to decide for the
commencement of therapy.
Our study failed to establish any association between serum
HBV DNA levels and liver histology in HBeAg-positive patients. A
possible explanation is that in these patients, the immune-
mediated response during immune clearance may lead to
fluctuating viremic levels with varying degrees of abnormalities
in histology [33]. Several non-invasive predictive indices involving
HBeAg-positive patients proposed in recent studies have also not
included serum HBV DNA as a factor for prediction [13,14].
Serum HBV DNA levels are of greater predictive value in HBeAg-
negative patients [34].
While the exact mechanism for the inverse relationship between
the HBsAg levels and the degree of fibrosis remains to be
examined, it may be related to the different stages of immune
clearance. HBsAg is found extensively in immunohistochemical
staining of liver histology in the immune tolerance phase [29].
With the transition from immune tolerance to early immune
clearance, the immune system starts to increase its magnitude of
immune control on the HBV. Serum HBsAg levels still remain
high at the transition from immune tolerance to early immune
clearance phase (ALT level may be at the high normal range) and
it is to be expected that there will be minimal fibrosis because
immune mediated attack is still of low magnitude. Upon entering
into a more full-blown stage of immune clearance with repeatedly
greater immune mediated damage, more fibrosis develops, and
viral control is achieved with decreasing HBsAg levels. HBsAg
production could also be influenced by the development of preS/S
mutants during immune clearance [35].
Intriguingly, high HBsAg levels are not always favorable in
CHB, as shown by recent studies demonstrating high HBsAg levels
to be associated with the development of HCC [36,37]. Hence,
further longitudinal studies should be performed to examine the
exact relationship between severity of fibrosis, disease progression
and HBsAg levels by serial HBsAg measurement. Studies
including non-Asian CHB patients would also be important, since
such patients are infected later in life, with the classical immune
tolerant phase absent or very short, and could well demonstrate
different results.
Our study employed the lowered ULN for ALT (30 U/L for
men, 19 U/L for women) as recommended by current treatment
guidelines. Therefore, our cohort of patients with ALT #26ULN
accurately represents the HBeAg-positive population in which
assessment of histologic severity is essential before deciding on
treatment. In addition, the assay used for serum HBsAg
measurement in our study has a broad dynamic range, minimizing
the potential errors related to manual dilution in the measurement
of high levels. Our study is limited by the lack of non-Asian CHB
patients. In addition, HBV genotyping was not performed in our
study, although prior studies have shown genotypes B and C, the
two common genotypes in Hong Kong, have a similar risk of
advanced fibrosis and histologic progression [38,39]. Future
studies involving different CHB populations with different
genotypes are required to validate our findings. The comparison
of the predictive value of HBsAg levels (including for HBeAg-
negative histology) with different non-invasive predictive indices
Table 2. Area under the receiver operating characteristic curve of serum HBsAg levels in predicting minor histologic changes.
AUC Standard Error p value 95% CI
Insignificant fibrosis (F #1) All patients (n = 140) 0.771 0.040 ,0.001 0.692–0.851
ALT #26ULN (n = 56) 0.869 0.054 ,0.001 0.763–0.976
Insignificant necroinflammation
(Knodell HAI #4)
All patients (n = 140) 0.546 0.053 0.393 0.442–0.650
ALT #62 ULN (n = 56) 0.532 0.080 0.697 0.376–0.698
F, Ishak fibrosis score; HAI, histologic activity index; ALT, alanine aminotransferase; ULN, upper limit of normal; AUC, area under curve; CI, confidence interval.
doi:10.1371/journal.pone.0043087.t002
Table 3. Sensitivity, specificity and predictive values of different HBsAg levels for predicting insignificant fibrosis among patients
with ALT #26ULN (n = 56).
HBsAg (IU/mL)
Number of
patients Sensitivity Specificity PPV NPV LR+ LR2
$10,000 45 90.9% 58.3% 88.9% 63.6% 2.18 0.16
$25,000 41 86.4% 75.0% 92.7% 60.0% 3.46 0.18
$50,000 32 68.2% 83.3% 93.8% 41.7% 4.08 0.38
$75,000 24 52.3% 91.7% 95.8% 34.4% 6.30 0.52
$100,000 16 36.4% 100% 100% 30.0% – 0.64
Insignificant fibrosis defined as Ishak fibrosis score #1.
HBsAg, hepatitis B surface antigen; ALT, alanine aminotransferase; ULN, upper limit of normal; PPV, positive predictive value; NPV, negative predictive value, LR+,
positive likelihood ratio; LR-, negative likelihood ratio.
doi:10.1371/journal.pone.0043087.t003
HBsAg Levels and Fibrosis in Chronic Hepatitis B
PLOS ONE | www.plosone.org 6 August 2012 | Volume 7 | Issue 8 | e43087
(e.g. the asparate aminotransferase/platelet ratio index) and
transient elastography are also needed. In additional, future
clinical and cost-effectgive studies with larger cohorts, after the
adjustment of HBV genotype, could consider fitting HBsAg levels
and other available non-invasive markers as an algorithm for
practical clinical usage.
In conclusion, serum HBsAg $25,000 IU/mL was indepen-
dently associated with insignificant fibrosis. This level accurately
predicted insignificant fibrosis in HBeAg-positive CHB patients
with ALT #26ULN (AUROC 0.869, positive predictive value
92.7%), the group of patients in which histologic evaluation is
recommended. Measurement of serum HBsAg levels can thus
assist treatment decisions among HBeAg-positive patients and
potentially reduce the need for liver biopsies.
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